Paris

• Comparison of two prophylactic antibiotic regimens in case of preterm prelabor rupture of membranes before 34 weeks of gestation: a randomiz … Pending
  2025-520842-31-00 5 Population of study participants Pregnant women with PPROM at 22 to 33
• Optimal Duration of Antibiotic Therapy in Drained Pyogenic Liver Abscess: 3 weeks versus 6 weeks, a non-inferiority trial Pending
  2025-520940-14-00 6 Pyogenic liver abscess
• Phase I clinical trial evaluating TG4070 in patients with non-small cell lung cancer Pending
  2025-520946-31-00 1 Non-Small Cell Lung Cancer
• A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed mult … Pending
  2025-520976-25-00 4 Relapsed/refractory multiple myeloma
• Efficacy of an empirical treatment with Amoxicillin-clavulanate (AC) compared to the combination Amoxicillin-clavulanate and Ciprofloxacin ( … Pending
  2025-520995-24-00 5 Adult patients treated for haematological disorders, in whom chemother
• A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refrac … Pending
  2025-521090-14-00 4 Patients with relapsed/refractory symptomatic multiple myeloma (MM)
• BeCALM - Brentuximab vedotin in CutAneous T-cell Lymphomas (CTCL): post-allogeneic hematopoietic stem cell transplant Maintenance Pending
  2025-521093-34-00 5 rare disease
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending
  2025-521113-13-00 10 Early Parkinson’s Disease
• CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental di … Pending
  2025-521161-27-00 4 Children and adolescents with severe neurodevelopmental disorders
• Study PACIFIC: Fixed duration treatment with combined pirtobrutinib and short course immuno-chemotherapy in fit patients with previously unt … Pending
  2025-521199-80-00 4 Patients with previously untreated symptomatic chronic lymphocytic leu
• Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad … Pending
  2025-521221-32-00 5 Advanced or Metastatic Non-Small Cell Lung Cancer
• FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onur … Pending
  2025-521322-14-00 4 Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation,
• MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease Pending
  2025-521331-36-00 10 Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%)
• PALETTE - Trial for personalisation of sepsis treatment in children and adults Pending
  2025-521371-31-00 4 Sepsis
• A Study to Compare the Effectiveness and Safety of T1695 (0.1% Tacrolimus) Versus Ciclosporin in Participants With Moderate to Severe Vernal … Pending
  2025-521567-12-00 4 Vernal Keratoconjunctivitis (VKC)
• PREV-CART - “A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiot … Pending
  2025-521571-30-00 5 Young Adults and adults with R/R B-cell acute lymphoblastic leukemia (
• A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu … Pending
  2025-521587-35-00 5 Metastatic colorectal cancer
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending
  2025-521590-13-00 5 Moderately to Severely Active Crohn’s Disease
• Study evaluating two treatment strategies for rectal cancer in patients ≥75 years old Pending
  2025-521619-37-00 5 Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to r
• Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with o … Pending
  2025-521632-12-00 5 Patients on Factor Xa inhibitor treatment needing an urgent interventi
• A phase 1/2 study of subcutaneous blinatumomab administration in children with R/R and MRD+ B-ALL Pending
  2025-521671-31-00 9 Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+)
• A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants Pending
  2025-521713-57-00 7 Noninfectious Uveitis
• Impact of the timing of immunotherapy administration in metastatic lung cancers Pending
  2025-521891-78-00 5 Adult patients with stage IV non squamous non-small cell lung cancer (
• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after … Pending
  2025-521908-22-00 10 EGFR-mutated Non-small Cell Lung Cancer

Showing 145–168 of 2,286 trials